Liposomal doxorubicin: the good, the bad and the not-so-ugly

J. Szebeni, Gyula Fülöp, L. Dézsi, Josbert Maarten Metselaar, Gerrit Storm

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)
34 Downloads (Pure)


There are direct and indirect indications that PEGylated liposomal doxorubicin (Doxil), a widely used anticancer nanomedicine, has a subclinical immune suppressive effect. As an example of a seemingly bad pharmacological property turning out to be “not-so-ugly”, but actually beneficial, the authors highlight the potential benefits of Doxil's immune suppressive effect. These include (1) the decreased uptake of the drug by the MPS which may entail enhanced tumor uptake, and, hence, improved therapeutic efficacy; (2) the use of slow infusion protocols in reducing the risk of hypersensitivity (infusion) reactions; and (3), possible protection against hypersensitivity reactions to co-administered reactogenic drugs. To consider immune suppression as useful represents a paradigm shifts in nanotoxicology and anticancer chemotherapy.
Original languageEnglish
Pages (from-to)765-767
JournalJournal of drug targeting
Issue number9
Publication statusPublished - 2016


  • 2023 OA procedure


Dive into the research topics of 'Liposomal doxorubicin: the good, the bad and the not-so-ugly'. Together they form a unique fingerprint.

Cite this